BR112019001193A2 - uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele - Google Patents
uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de peleInfo
- Publication number
- BR112019001193A2 BR112019001193A2 BR112019001193-5A BR112019001193A BR112019001193A2 BR 112019001193 A2 BR112019001193 A2 BR 112019001193A2 BR 112019001193 A BR112019001193 A BR 112019001193A BR 112019001193 A2 BR112019001193 A2 BR 112019001193A2
- Authority
- BR
- Brazil
- Prior art keywords
- ocs
- skin
- treat inflammatory
- lesions
- oxygenated cholesterol
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title abstract 3
- 206010040882 skin lesion Diseases 0.000 title abstract 3
- 231100000444 skin lesion Toxicity 0.000 title abstract 3
- -1 Cholesterol Sulfates Chemical class 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 2
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamató- ria e lesões de pele". a presente invenção refere-se a métodos de tratamento e tratamento profilático de doenças de pele inflamatórias e lesões de pele. por exemplo, os métodos podem envolver contato da pele com um sulfato de colesterol oxigeno (ocs), por exemplo, 5-colesten-3, 2,5-dio, 3- sulfato (25hc3s) ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370036P | 2016-08-02 | 2016-08-02 | |
US62/370,036 | 2016-08-02 | ||
US201762470576P | 2017-03-13 | 2017-03-13 | |
US62/470,576 | 2017-03-13 | ||
PCT/US2017/044821 WO2018026767A1 (en) | 2016-08-02 | 2017-08-01 | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019001193A2 true BR112019001193A2 (pt) | 2019-04-30 |
Family
ID=61073120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001193-5A BR112019001193A2 (pt) | 2016-08-02 | 2017-08-01 | uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190374554A1 (pt) |
EP (1) | EP3493671A4 (pt) |
JP (2) | JP2019524774A (pt) |
KR (2) | KR102568036B1 (pt) |
CN (1) | CN109862787A (pt) |
AU (2) | AU2017306140A1 (pt) |
BR (1) | BR112019001193A2 (pt) |
CA (1) | CA3031211A1 (pt) |
IL (1) | IL264389A (pt) |
MX (1) | MX2019001324A (pt) |
TW (2) | TW201818944A (pt) |
WO (1) | WO2018026767A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
TWI816417B (zh) | 2013-12-24 | 2023-09-21 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽(ocs)之用途 |
KR20230152787A (ko) | 2016-08-02 | 2023-11-03 | 버지니아 커먼웰스 유니버시티 | 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물 |
CA3170320A1 (en) * | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
CN113040140B (zh) * | 2021-01-28 | 2022-06-03 | 菲吉乐科(南京)生物科技有限公司 | 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用 |
CN113521094A (zh) * | 2021-05-23 | 2021-10-22 | 广州奇维生物信息技术有限公司 | 一种治疗湿疹的乳剂软膏及其制备方法 |
CN114646702B (zh) * | 2022-03-03 | 2023-01-06 | 四川大学华西医院 | 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
US20120253143A1 (en) * | 2011-04-04 | 2012-10-04 | Raphael Warren | Method of measuring a skin agent transferred to skin |
PT2836502T (pt) | 2012-04-12 | 2017-10-27 | Univ Virginia Commonwealth | Um novo metabolito de colesterol, 5-colesten, 3, 25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças do fígado gorduroso e aterosclerose |
TWI816417B (zh) * | 2013-12-24 | 2023-09-21 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽(ocs)之用途 |
-
2017
- 2017-08-01 TW TW106125933A patent/TW201818944A/zh unknown
- 2017-08-01 TW TW111139507A patent/TW202308651A/zh unknown
- 2017-08-01 AU AU2017306140A patent/AU2017306140A1/en not_active Abandoned
- 2017-08-01 CN CN201780048064.0A patent/CN109862787A/zh active Pending
- 2017-08-01 BR BR112019001193-5A patent/BR112019001193A2/pt not_active Application Discontinuation
- 2017-08-01 MX MX2019001324A patent/MX2019001324A/es unknown
- 2017-08-01 EP EP17837507.7A patent/EP3493671A4/en active Pending
- 2017-08-01 KR KR1020197005444A patent/KR102568036B1/ko active IP Right Grant
- 2017-08-01 KR KR1020237027532A patent/KR20230124756A/ko not_active Application Discontinuation
- 2017-08-01 JP JP2019505256A patent/JP2019524774A/ja active Pending
- 2017-08-01 US US16/320,400 patent/US20190374554A1/en not_active Abandoned
- 2017-08-01 CA CA3031211A patent/CA3031211A1/en active Pending
- 2017-08-01 WO PCT/US2017/044821 patent/WO2018026767A1/en unknown
-
2019
- 2019-01-22 IL IL264389A patent/IL264389A/en unknown
-
2020
- 2020-10-16 US US17/072,994 patent/US20210169902A1/en active Pending
-
2021
- 2021-11-15 JP JP2021185644A patent/JP2022031733A/ja active Pending
-
2022
- 2022-07-13 AU AU2022205208A patent/AU2022205208A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018026767A1 (en) | 2018-02-08 |
TW202308651A (zh) | 2023-03-01 |
AU2022205208A1 (en) | 2022-08-04 |
TW201818944A (zh) | 2018-06-01 |
JP2019524774A (ja) | 2019-09-05 |
KR102568036B1 (ko) | 2023-08-17 |
EP3493671A4 (en) | 2020-04-08 |
CN109862787A (zh) | 2019-06-07 |
EP3493671A1 (en) | 2019-06-12 |
JP2022031733A (ja) | 2022-02-22 |
US20210169902A1 (en) | 2021-06-10 |
AU2017306140A1 (en) | 2019-02-21 |
CA3031211A1 (en) | 2018-02-08 |
MX2019001324A (es) | 2019-07-04 |
US20190374554A1 (en) | 2019-12-12 |
KR20230124756A (ko) | 2023-08-25 |
IL264389A (en) | 2019-02-28 |
KR20190032530A (ko) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001193A2 (pt) | uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele | |
CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
BR112019006876A2 (pt) | anticorpos e composições anti-lag-3 | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
MX2022006072A (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
BR112018069023A2 (pt) | métodos de tratamento de doenças colestáticas | |
GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
BR112013018919A2 (pt) | composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos | |
EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112019004353A2 (pt) | métodos e vetores para tratar distúrbios do cns | |
BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
WO2018115432A3 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE | |
EP3558340A4 (en) | METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
BR112019002719A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em métodos relacionados a doenças de depósito lisossômico | |
CY1120835T1 (el) | Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 1/02 , A61K 31/575 Ipc: A61K 31/575 (2006.01), A61K 47/10 (2017.01), A61K |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |